共 184 条
[1]
Holmes D(2012)FDA paves the way for pre-exposure HIV prophylaxis Lancet 380 325-2599
[2]
Grant RM(2010)Preexposure chemoprophylaxis for HIV prevention in men who have sex with men N Engl J Med 363 2587-410
[3]
Lama JR(2012)Antiretroviral prophylaxis for HIV prevention in heterosexual men and women N Engl J Med 367 399-434
[4]
Anderson PL(2012)Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana N Engl J Med 367 423-172
[5]
McMahan V(2007)Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies Curr HIV/AIDS Rep. 4 165-1008
[6]
Liu AY(2008)Changes in sexual risk behavior among participants in a PrEP HIV prevention trial Sex Transm Dis 35 1002-1028
[7]
Vargas L(2013)No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis PLoS ONE 8 e81997-60
[8]
Baeten JM(2013)Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis Lancet Infect Dis. 13 1021-30
[9]
Donnell D(2017)Acceptability of an open-label wait-listed trial design: experiences from the PROUD PrEP study PLoS ONE 12 e0175596-1313
[10]
Ndase P(2016)Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial Lancet 387 53-206